Research & Literature

Late onset aura may herald cerebral amyloid angiopathy: A case report.

Samanci B, Coban O, Baykan B

Cephalalgia : an international journal of headache 2016; (36(10)):998-1001 doi:10.1177/0333102415620253.

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP.

Nizetic D, Chen CL, Hong W, Koo EH

Frontiers in behavioral neuroscience 2015; (9()):299 doi:10.3389/fnbeh.2015.00299.

Acute Convexity Subarachnoid Hemorrhage Related to Cerebral Amyloid Angiopathy: Clinicoradiological Features and Outcome.

Calviere L, Cuvinciuc V, Raposo N, et al.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016; (25(5)):1009-1016 doi:10.1016/j.jstrokecerebrovasdis.2015.11.010.

Converging approaches to understanding early onset familial Alzheimer disease: A First Nation study.

Cabrera LY, Beattie BL, Dwosh E, Illes J

SAGE open medicine 2015; (3()):2050312115621766 doi:10.1177/2050312115621766.

Cerebral Microbleeds and Cortical Superficial Siderosis in Patients Presenting With Minor Cerebrovascular Events.

Zerna C, Modi J, Bilston L, et al.

Stroke 2016; (47(9)):2236-41 doi:10.1161/STROKEAHA.116.013418.

Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy.

van Etten ES, Gurol ME, van der Grond J, et al.

Neurology 2016; (87(14)):1482-1487 doi:10.1212/WNL.0000000000003181.

Cortical superficial siderosis predicts early recurrent lobar hemorrhage.

Roongpiboonsopit D, Charidimou A, William CM, et al.

Neurology 2016; (87(18)):1863-1870 doi:10.1212/WNL.0000000000003281.

APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review.

Sellal F, Wallon D, Martinez-Almoyna L, et al.

Journal of Alzheimer's disease : JAD 2017; (56(1)):37-46 doi:10.3233/JAD-160709.

Antithrombotic therapy in patients with cerebral microbleeds.

Wilson D, Werring DJ

Current opinion in neurology 2017; (30(1)):38-47 doi:10.1097/WCO.0000000000000411.

Cerebral Amyloid Angiopathy in Stroke Medicine.

Block F, Dafotakis M

Deutsches Arzteblatt international 2017; (114(3)):37-42.

Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis.

Charidimou A, Imaizumi T, Moulin S, et al.

Neurology 2017; (89(8)):820-829 doi:10.1212/WNL.0000000000004259.

Cerebral amyloid angiopathy as a cause of neurodegeneration.

Smith EE

Journal of neurochemistry 2018; (144(5)):651-658 doi:10.1111/jnc.14157.

The growing clinical spectrum of cerebral amyloid angiopathy.

Wermer MJH, Greenberg SM

Current opinion in neurology 2018; (31(1)):28-35 doi:10.1097/WCO.0000000000000510.

The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

Tugwell-Allsup J, Pritchard AW

Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease.

Mann DMA, Davidson YS, Robinson AC, et al.

Acta neuropathologica 2018; (136(4)):569-587 doi:10.1007/s00401-018-1866-3.

Cerebral amyloid angiopathy: diagnosis and potential therapies.

Weber SA, Patel RK, Lutsep HL

Expert review of neurotherapeutics 2018; (18(6)):503-513 doi:10.1080/14737175.2018.1480938.

The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation.

Cannistraro RJ, Meschia JF

Current cardiology reports 2018; (20(11)):106 doi:10.1007/s11886-018-1052-1.

Cerebral amyloid angiopathy-related transient focal neurological episodes: A transient ischemic attack mimic with an increased risk of intracranial hemorrhage.

Vales-Montero M, García-Pastor A, Iglesias-Mohedano AM, et al.

Journal of the neurological sciences 2019; (406()):116452 doi:10.1016/j.jns.2019.116452.

Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA.

Stanton JED, Chandratheva A, Wilson D, et al.

Journal of neurology 2020; (267(1)):133-137 doi:10.1007/s00415-019-09558-9.

Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.

Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al.

Nature reviews. Neurology 2020; (16(1)):30-42 doi:10.1038/s41582-019-0281-2.

Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: A prognostic marker.

Raposo N, Charidimou A, Roongpiboonsopit D, et al.

Neurology 2020; (94(9)):e968-e977 doi:10.1212/WNL.0000000000009036.

Migraine With Aura as Early Disease Marker in Hereditary Dutch-Type Cerebral Amyloid Angiopathy.

Koemans EA, Voigt S, Rasing I, et al.

Stroke 2020; (51(4)):1094-1099 doi:10.1161/STROKEAHA.119.028170.

Hereditary cerebral amyloid angiopathy, Piedmont-type mutation.

Kozberg MG, van Veluw SJ, Frosch MP, Greenberg SM

Neurology. Genetics 2020; (6(2)):e411 doi:10.1212/NXG.0000000000000411.

An APP mutation family exhibiting white matter hyperintensities and cortical calcification in East China.

Yi Y, Xiaobin Y, Hui C, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(10)):2921-2928 doi:10.1007/s10072-020-04342-4.

Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen.

Cajamarca SA, Norris EH, van der Weerd L, et al.

Proceedings of the National Academy of Sciences of the United States of America 2020; (117(25)):14482-14492 doi:10.1073/pnas.1921327117.

Communication and Team Interactions to Improve Patient Experiences, Quality of Care, and Throughput in MRI.

Ajam AA, Tahir S, Makary MS, et al.

Topics in magnetic resonance imaging : TMRI 2020; (29(3)):131-134 doi:10.1097/RMR.0000000000000242.

Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort.

Schrag M, Mac Grory B, Nackenoff A, et al.

Translational stroke research 2021; (12(2)):259-265 doi:10.1007/s12975-020-00838-5.

Blood Pressure and Outcomes in Patients With Different Etiologies of Intracerebral Hemorrhage: A Multicenter Cohort Study.

Zhang S, Wang Z, Zheng A, et al.

Journal of the American Heart Association 2020; (9(19)):e016766 doi:10.1161/JAHA.120.016766.

New horizons: managing antithrombotic dilemmas in patients with cerebral amyloid angiopathy.

Kelly J

Age and ageing 2021; (50(2)):347-355 doi:10.1093/ageing/afaa275.

Cerebral amyloid angiopathy-related inflammation: current status and future implications.

Wu JJ, Yao M, Ni J

Chinese medical journal 2021; (134(6)):646-654 doi:10.1097/CM9.0000000000001427.

Occipital Cortical Calcifications in Cerebral Amyloid Angiopathy.

Rasing I, Voigt S, Koemans EA, et al.

Stroke 2021; (52(5)):1851-1855 doi:10.1161/STROKEAHA.120.033286.

Cerebral Amyloid Angiopathy-Related Transient Focal Neurologic Episodes.

Smith EE, Charidimou A, Ayata C, et al.

Neurology 2021; (97(5)):231-238 doi:10.1212/WNL.0000000000012234.

APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines.

Xiao X, Liu H, Liu X, et al.

Frontiers in aging neuroscience 2021; (13()):695808 doi:10.3389/fnagi.2021.695808.

Recurrent migraine aura-like symptoms in an elderly woman: symptomatic cortical spreading depression?

Glössmann K, Baumgartner C, Koren JP, Riederer F

BMJ case reports 2021; (14(7)) doi:10.1136/bcr-2020-241479.

Early-Onset Cerebral Amyloid Angiopathy and Alzheimer Disease Related to an APP Locus Triplication.

Grangeon L, Cassinari K, Rousseau S, et al.

Neurology. Genetics 2021; (7(5)):e609 doi:10.1212/NXG.0000000000000609.

[Intracerebral hemorrhage under platelet inhibition and oral anticoagulation in patients with cerebral amyloid angiopathy].

Haußmann R, Homeyer P, Haußmann M, et al.

Der Nervenarzt 2022; (93(6)):599-604 doi:10.1007/s00115-021-01206-w.

Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death: A Systematic Review and Meta-analysis.

Sanchez-Caro JM, de Lorenzo Martínez de Ubago I, de Celis Ruiz E, et al.

JAMA neurology 2022; (79(1)):38-47 doi:10.1001/jamaneurol.2021.3989.

Spatial and temporal intracerebral hemorrhage patterns in Dutch-type hereditary cerebral amyloid angiopathy.

Voigt S, Amlal S, Koemans EA, et al.

International journal of stroke : official journal of the International Stroke Society 2022; (17(7)):793-798 doi:10.1177/17474930211057022.

Longitudinal Progression of Magnetic Resonance Imaging Markers and Cognition in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.

van Dijk SE, van der Grond J, Lak J, et al.

Stroke 2022; (53(6)):2006-2015 doi:10.1161/STROKEAHA.121.035826.

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.

Withington CG, Turner RS

Frontiers in neurology 2022; (13()):862369 doi:10.3389/fneur.2022.862369.

Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy.

Shirzadi Z, Yau WW, Schultz SA, et al.

Annals of neurology 2022; (92(3)):358-363 doi:10.1002/ana.26429.

The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.

Charidimou A, Boulouis G, Frosch MP, et al.

The Lancet. Neurology 2022; (21(8)):714-725 doi:10.1016/S1474-4422(22)00208-3.

Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases.

Schoenmaekers JJAO, Bruinsma J, Wolfs C, et al.

JTO clinical and research reports 2022; (3(10)):100401 doi:10.1016/j.jtocrr.2022.100401.

Primary acute convexity subarachnoid hemorrhage in older patients: analysis of baseline, clinical and MRI characteristics including quantitative surface study and topographical probabilistic mapping of convexity subarachnoid hemorrhage.

Autieri V, Gaillard N, Mourand I, et al.

Acta neurologica Belgica 2023; (123(2)):519-527 doi:10.1007/s13760-022-02115-8.

Main features of hereditary cerebral amyloid angiopathies: A systematic review.

Biffi A

Cerebral circulation - cognition and behavior 2022; (3()):100124 doi:10.1016/j.cccb.2022.100124.

Percutaneous left atrial appendage closure: beyond the classic indications.

Guérios EE, Chamié F

AsiaIntervention 2023; (9(1)):70-77 doi:10.4244/AIJ-D-22-00040.

"Scanxiety" and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up - a qualitative study.

Seibel K, Sauer B, Wagner B, Becker G

BMC psychology 2023; (11(1)):119 doi:10.1186/s40359-023-01151-0.

Phenotype and imaging features associated with APP duplications.

Grangeon L, Charbonnier C, Zarea A, et al.

Alzheimer's research & therapy 2023; (15(1)):93 doi:10.1186/s13195-023-01172-2.

Progression of cerebral amyloid angiopathy: a pathophysiological framework.

Koemans EA, Chhatwal JP, van Veluw SJ, et al.

The Lancet. Neurology 2023; (22(7)):632-642 doi:10.1016/S1474-4422(23)00114-X.

Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.

Schilling S, Pradhan A, Heesch A, et al.

Acta neuropathologica communications 2023; (11(1)):87 doi:10.1186/s40478-023-01577-y.

Lecanemab: Appropriate Use Recommendations.

Cummings J, Apostolova L, Rabinovici GD, et al.

The journal of prevention of Alzheimer's disease 2023; (10(3)):362-377 doi:10.14283/jpad.2023.30.

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).

McKay NS, Gordon BA, Hornbeck RC, et al.

Nature neuroscience 2023; (26(8)):1449-1460 doi:10.1038/s41593-023-01359-8.

Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.

Inoue Y, Shue F, Bu G, Kanekiyo T

Molecular neurodegeneration 2023; (18(1)):46 doi:10.1186/s13024-023-00640-5.

Cerebral amyloid angiopathy: Neuropathological diagnosis, link to Alzheimer's disease and impact on clinics.

Thal DR, Gawor K

Clinical neuropathology 2023; (42(5)):176-189 doi:10.5414/NP301564.

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA.

Sin MK, Zamrini E, Ahmed A, et al.

Journal of clinical medicine 2023; (12(21)) doi:10.3390/jcm12216792.

Risk factors for recurrent cerebral amyloid angiopathy-related intracerebral hemorrhage.

Jia X, Bo M, Zhao H, et al.

Frontiers in neurology 2023; (14()):1265693 doi:10.3389/fneur.2023.1265693.

Validation of 3- and 5-point severity scales to assess ARIA-E.

Bracoud L, Klein G, Lyons M, et al.

Alzheimer's & dementia (Amsterdam, Netherlands) 2023; (15(4)):e12503 doi:10.1002/dad2.12503.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Sensitivity of the Boston criteria version 2.0 in Dutch-type hereditary cerebral amyloid angiopathy.

van der Zwet R, Koemans EA, Voigt S, et al.

International journal of stroke : official journal of the International Stroke Society 2024; (19(8)):942-946 doi:10.1177/17474930241239801.

Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.

Koemans EA, Rasing I, Voigt S, et al.

Stroke 2024; (55(4)):954-962 doi:10.1161/STROKEAHA.123.044688.

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Honig LS, Sabbagh MN, van Dyck CH, et al.

Alzheimer's research & therapy 2024; (16(1)):105 doi:10.1186/s13195-024-01441-8.

Cerebral haemorrhage in the patient with atrial fibrillation: do we employ the direct oral anticoagulants without waiting too long?

Vassiliki' Coutsoumbas G, Di Pasquale G

European heart journal supplements : journal of the European Society of Cardiology 2024; (26(Suppl 1)):i64-i68 doi:10.1093/eurheartjsupp/suae020.

Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0.

Weidauer S, Tafreshi M, Förch C, et al.

European journal of neurology 2024; (31(10)):e16425 doi:10.1111/ene.16425.

15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.

Daniels AJ, McDade E, Llibre-Guerra JJ, et al.

medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.08.08.24311689.

Cognition in (pre)symptomatic Dutch-type hereditary and sporadic cerebral amyloid angiopathy.

van Dort R, Kaushik K, Rasing I, et al.

Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; (20(11)):7518-7528 doi:10.1002/alz.14171.

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association.

Park KH, Kim GH, Kim CH, et al.

Dementia and neurocognitive disorders 2024; (23(4)):165-187 doi:10.12779/dnd.2024.23.4.165.

The Impact of Vascular Risk Factors on Cerebral Amyloid Angiopathy: A Cohort Study in Hereditary Cerebral Amyloid Angiopathy and a Systemic Review in Sporadic Cerebral Amyloid Angiopathy.

Voigt S, Voigt S, Rasing I, et al.

Cerebrovascular diseases (Basel, Switzerland) 2025; (54(5)):746-760 doi:10.1159/000542666.

Left atrial appendage occlusion in patients with atrial fibrillation and intracerebral haemorrhage associated with cerebral amyloid angiopathy: a multicentre observational study and pooled analysis of published studies.

Thiankhaw K, Best J, Srivastava S, et al.

Journal of neurology, neurosurgery, and psychiatry 2025; (96(6)):528-536 doi:10.1136/jnnp-2024-334718.

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms.

Greenberg SM, Bax F, van Veluw SJ

Nature reviews. Neurology 2025; (21(4)):193-203 doi:10.1038/s41582-024-01053-8.

A de novo, mosaic and complex chromosome 21 rearrangement causes APP triplication and familial autosomal dominant early onset Alzheimer disease.

Ehn E, Eisfeldt J, Laffita-Mesa JM, et al.

Scientific reports 2025; (15(1)):2912 doi:10.1038/s41598-025-86645-0.

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.

Zimmer JA, Ardayfio P, Wang H, et al.

JAMA neurology 2025; (82(5)):461-469 doi:10.1001/jamaneurol.2025.0065.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis.

Jeong SY, Suh CH, Lim JS, et al.

Neurology 2025; (104(8)):e213483 doi:10.1212/WNL.0000000000213483.

Donanemab: Appropriate use recommendations.

Rabinovici GD, Selkoe DJ, Schindler SE, et al.

The journal of prevention of Alzheimer's disease 2025; (12(5)):100150 doi:10.1016/j.tjpad.2025.100150.

Characterizing surveillance-associated anxiety following curative-intent surgery for gastrointestinal cancer: a mixed methods approach.

Bath NM, Khatri R, Quinn PL, et al.

Journal of cancer survivorship : research and practice 2025; doi:10.1007/s11764-025-01781-w.

Fatal Outcome of Intravenous Thrombolysis With an Unexpected Finding of Amyloid-β-Related Angiitis-A Case Report Highlighting a Relevant Scenario With Acute Focal Neurological Deficits and Minimal Radiological Presentation.

Babarczy K, Radics BL, Horvath O, et al.

Neuropathology : official journal of the Japanese Society of Neuropathology 2025; (45(4)):e70013 doi:10.1111/neup.70013.

Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization.

Cordonnier C, Klijn C, Smith EE, et al.

International journal of stroke : official journal of the International Stroke Society 2025; (20(8)):949-967 doi:10.1177/17474930251365861.

Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers.

Schreiber CP, Kovacik A, Bishop J, Helman J

Drugs & aging 2025; (42(12)):1103-1111 doi:10.1007/s40266-025-01253-x.

Cerebral Amyloid Angiopathy Imaging Markers, Radiological Boston Criteria, and Thrombolysis Outcomes in Ischemic Stroke.

Marzoughi S, Alhabli I, Singh N, et al.

Stroke 2026; (57(4)):933-944 doi:10.1161/STROKEAHA.125.054654.

15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.

Daniels AJ, McDade E, Llibre-Guerra JJ, et al.

NPJ dementia 2026; (2(1)):13 doi:10.1038/s44400-025-00047-7.

Posterior confluent white matter hyperintensities and intracerebral hemorrhage recurrence risk in patients with cerebral amyloid angiopathy.

Liu J, Liu F, Wang Z, et al.

Frontiers in neurology 2026; (17()):1767088 doi:10.3389/fneur.2026.1767088.

Atrial fibrillation and coexisting cerebral amyloid angiopathy: safety and efficacy of transcatheter left atrial appendage occlusion.

Gurgoglione FL, Barocelli F, Solinas E, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

Cerebral Amyloid Angiopathy Presenting as Lobar Intracerebral Hemorrhage with Cognitive Decline in an 80-Year-Old Patient: A Clinicoradiologic Case Report.

Tarabocchia R, Javaid K, Mittal R, et al.

Reports (MDPI) 2026; (9(2)) doi:10.3390/reports9020191.

Cognitive decline in Dutch-type hereditary and sporadic cerebral amyloid angiopathy: a 5-year follow-up study.

van Dort R, van Stek-Smits VCJ, Schriemer SE, et al.

Alzheimer's & dementia : the journal of the Alzheimer's Association 2026; (22(7)):e71629 doi:10.1002/alz.71629.

Measuring "Scanxiety": A Systematic Review and Symptom Coverage Analysis of Commonly Used Measures.

Bullock K, Rawlings GH, Lee G, et al.

Radiography (London, England : 1995) 2026; (32(6)):103488 doi:10.1016/j.radi.2026.103488.

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials.

Vamanu A, Mastaleru A, Schreiner TG, et al.

Medical sciences (Basel, Switzerland) 2026; (14(3)) doi:10.3390/medsci14030337.

Distinct amyloid-β filament fold in individuals with APP Flemish mutation.

Khaki PSS, Guillen-Poza PA, Wong C, et al.

Nature structural & molecular biology 2026; (33(8)):1194-1203 doi:10.1038/s41594-026-01855-y.

Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions.

Zupan M, Prelog PR, Kramberger MG, Frol S

Frontiers in neurology 2026; (17()):1889769 doi:10.3389/fneur.2026.1889769.

Before the bolus: why anti-amyloid therapy must become part of every stroke code.

Khaliq AS, Khan K

Annals of medicine and surgery (2012) 2026; (88(9)):5550-5553 doi:10.1097/MS9.0000000000005585.

Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab.

Demir ÜF, Karakuş Dilbaz F

Neurology international 2026; (18(9)) doi:10.3390/neurolint18090171.